2012 |
Dr. Holger Berk |
The legislative framework for veterinary medicinal products in Europe under revision - A review on primary objectives, key issues, policy options and their impact assessment |
|
|
2012 |
Prof. Dr. Dr. Thomas Bieber |
Stratified medicine: A new challenge for the academia, industry, regulators and patients *** |
|
|
2012 |
Christian Biegel |
EudraVigilance Medicinal Product Dictionary - a challenge for authorities and marketing authorisation holders |
|
|
2012 |
Jürgen Blömer |
User Safety Risk Assessment (USRA) - Part of the overall Risk / Benefit Assessment of veterinary medicinal products (VMP) in Europe |
|
|
2012 |
Nicole Dévaud |
Veterinary medicinal products authorised for rabbits in the European Union - Causes for insufficient availability and consequences on human and animal health *** |
|
|
2012 |
Dr. Axel Dienemann |
Pharmaceutical development of medicines for paediatric use - requirements, challenges and implications |
|
|
2012 |
Dr. Sven Enders |
Case Study: An In-Market Drug Approved for Several Indications - AMNOG and Its Impacts |
|
|
2012 |
Stephanie Gelsen |
Legislation around Wholesalers and Impact of new Developments of the EU GDP Guideline |
|
|
2012 |
Dr. Astrid Gerhardt |
Exceptional Japan filing of a biologic mature product |
|
|
2012 |
Christian Hanke |
Project-, Drug-, and Business Development in a Biotech SME *** |
|
|
2012 |
Ulrich Härtel |
Clinical trial standard protocols, approaches for more regulatory efficiency? *** |
|
|
2012 |
Dr. Martin M. Hartge |
HTA of orphan oncological medicinal products - A current critical assessment and discussion from authority, KOL and industry point of view |
|
|
2012 |
Pia Helfrich |
Investigator-Initiated Trials on Medical Devices - Legal Basis and Regulatory Aspects *** |
|
|
2012 |
Dr. Leonie Hempel |
Challenges and Chances of the Development of Biosimilar Monoclonal Antibodies in the EU |
|
|
2012 |
Dr. Matthias Hübner |
Worldwide Regulatory Strategy for the Development and Submission of a Recombinant Product antagonizing the Action of a Medicinal Product *** |
|
|
2012 |
Dr. Viktor Ivandic |
Methodological Requirements for Early Benefit Assessment in Germany (G-BA/ IQWIG) and Single Technology Appraisal in England (NICE) - a Comparison *** |
|
|
2012 |
Angelika Kamp |
2 years Variation Regulation: A retrospective critical assessment from the industrial perspective *** |
|
|
2012 |
Karen Koch |
An Overview of the Orphan Drug Status which has been put in place in countries in order to stimulate the research and development of treatments of rare diseases |
|
|
2012 |
Martina Krüger Haberkamp |
Das Qualitätsmanagement im Blutspendewesen am Beispiel des Blutspendedienstes der Bundeswehr |
|
|
2012 |
Judith Leyendecker |
Identification of Commercially Confidential Information and Protection of Personal Data - New transparency guidance (1st publication: June 2011) of EMA and HMA especially from the point of view of service companies |
|
|